GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that its Extraordinary General Meeting held today at 3:00 p.m. approved all resolutions submitted to shareholders, with the exception of the 8th resolution relating to a reserved capital increase, which was